Trials / Withdrawn
WithdrawnNCT03800784
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Study of 18F-DCFPyL PET/CT, for Detection of Radiological Progression in Patients With Metastatic (M+) and Non-metastatic (M0) Castration Resistant Prostate Cancer Receiving Standard Androgen Receptor Targeted Treatment
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic (nmCRPC) castration resistant prostate cancer who have evidence of biochemical (PSA) disease progression without evidence of radiological disease progression on conventional standard radiologic testing (99mTc-methylene diphosphonate bone scan and CT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-DCFPyL Injection | A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2021-10-21
- Completion
- 2021-10-21
- First posted
- 2019-01-11
- Last updated
- 2021-12-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03800784. Inclusion in this directory is not an endorsement.